Novartis’ Narasimhan sees unexpected lessons from COVID-19, and anticipates more: a BioCentury audio interview

The digital transformation of drug development that is being accelerated in response to the pandemic  will continue, according to Novartis CEO Vasant Narasimhan. However, there’s still a learning curve on whether the clinical and preclinical shortcuts introduced with the pandemic can be used more routinely.

In a BioCentury 2020 Back to School audio interview, Narasimhan discussed the legacies of the pandemic and how they might shape the decisions made by large biopharmaceutical companies such as Novartis AG (NYSE:NVS; SIX:NOVN). The interview was one of a series with key industry leaders as part of BioCentury’s Back to School 2020 multimedia content (see Cover Story:  “The Imperative of COVID-19”)...